After exiting stealth mode with $190M today, Marea Therapeutics' Co-Founder Ethan Weiss describes ANGPTL4 as a cardiometabolic target and more

blonca9
Jun 18, 2024
1 min read

Cardiology expert Ethan Weiss describes the difference between ANGPTL4 and ANGPLT3, the rationale for lowering remnant cholesterol, Marea's plans beyond this target, and his upcoming Timmerman Traverse hike for charity.

Recent Posts

See All

The CEO of Tennr, which raised a $101M series C earlier this summer, explains how the company's platform uses large language models to make the patient referral process to specialists more efficient

After exiting stealth with $20 million two weeks ago, Orchestra Bio is out to help science entrepreneurs handle the dollars and cents management and long term planning that business requires

IO Biotech CEO Mai-Britt Zocca discusses the phase 3 pivotal trial result of the cancer vaccine Cylembio in first line advanced melanoma - and the company's strategy ahead

After exiting stealth mode with $190M today, Marea Therapeutics' Co-Founder Ethan Weiss describes ANGPTL4 as a cardiometabolic target and more

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight